Heba Abdel-Aziz

Heba Abdel-Aziz

Auto-generated profile, based on publicly available information

Heba Abdel-Aziz

Scientific Department, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HAHeba Abdel-Aziz
Heba Abdel-Aziz
TWTimo Windeck
Timo Windeck
MPMichael Ploch
Michael Ploch
EVEugen J. Verspohl
Eugen J. Verspohl

1 February 2015 in Phytomedicine
Verified
Journal Article
Closed access
CWC. Weidner
C. Weidner
MRM. Rousseau
M. Rousseau
APA. Plauth
A. Plauth
SWS.J. Wowro
S.J. Wowro
CFC. Fischer
C. Fischer
SSS. Sauer
S. Sauer

1 May 2013 in Phytomedicine
Verified
Journal Article
Closed access
HAHeba Abdel-Aziz
Heba Abdel-Aziz
WWWalaa Wadie
Walaa Wadie
DADalaal M. Abdallah
Dalaal M. Abdallah
GLGeorg Lentzen
Georg Lentzen
MKMohamed T. Khayyal
Mohamed T. Khayyal

24 November 2013 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
CWChristopher Weidner
Christopher Weidner
SWSylvia J. Wowro
Sylvia J. Wowro
AFAnja Freiwald
Anja Freiwald
VKVitam Kodelja
Vitam Kodelja
HAHeba Abdel‐Aziz
Heba Abdel‐Aziz
SSSascha Sauer
Sascha Sauer

12 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CWChristopher Weidner
Christopher Weidner
SWSylvia J. Wowro
Sylvia J. Wowro
MRMorten Rousseau
Morten Rousseau
AFAnja Freiwald
Anja Freiwald
VKVitam Kodelja
Vitam Kodelja
SSSascha Sauer
Sascha Sauer
Given the significant increases in the incidence of metabolic diseases, efficient strategies for preventing and treating of these common disorders are urgently needed. This includes the development of phytopharmaceutical products or functional foods to prevent or cure metabolic diseases. Plant extracts from edible biomaterial provide a potential resource of structurally diverse molecules that can synergistically interfere with complex disorders. In this study we describe the safe application of ethanolic chamomile (Matricaria recutita) flowers extract (CFE) for the treatment and prevention of type 2 diabetes and associated disorders. We show in vitro that this extract activates in particular nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) and its isotypes. In a cellular context, in human primary adipocytes CFE administration (300 µg/ml) led to specific expression of target genes of PPARγ, whereas in human hepatocytes CFE-induced we detected expression changes of genes that were regulated by PPARα. In vivo treatment of insulin-resistant high-fat diet (HFD)-fed C57BL/6 mice with CFE (200 mg/kg/d) for 6 weeks considerably reduced insulin resistance, glucose intolerance, plasma triacylglycerol, non-esterified fatty acids (NEFA) and LDL/VLDL cholesterol. Co-feeding of lean C57BL/6 mice a HFD with 200 mg/kg/d CFE for 20 weeks showed effective prevention of fatty liver formation and hepatic inflammation, indicating additionally hepatoprotective effects of the extract. Moreover, CFE treatment did not reveal side effects, which have otherwise been associated with strong synthetic PPAR-targeting molecules, such as weight gain, liver disorders, hemodilution or bone cell turnover. Taken together, modulation of PPARs and other factors by chamomile flowers extract has the potential to prevent or treat type 2 diabetes and related disorders.

15 May 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
MSMohamed E. M. Saeed
Mohamed E. M. Saeed
NMNuha Mahmoud
Nuha Mahmoud
YSYoshikazu Sugimoto
Yoshikazu Sugimoto
Thomas EfferthThomas Efferth
Thomas Efferth
HAHeba Abdel-Aziz
Heba Abdel-Aziz
Betulinic acid (BetA) is a naturally occurring pentacyclic triterpene isolated from the outer bark of white-barked birch trees and many other medicinal plants. Here, we studied betulinic acid's cytotoxic activity against drug-resistant tumor cell lines. P-glycoprotein (MDR1/ABCB1) and BCRP (ABCG2) are known ATP-binding cassette (ABC) drug transporters that mediating MDR. ABCB5 is a close relative to ABCB1, which also mediates MDR. Constitutive activation of the EGF receptor is tightly linked to the development of chemotherapeutic resistance. BetA inhibited P-gp, BCRP, ABCB5 and mutation activated EGFR overexpressing cells with similar efficacy as their drug-sensitive parental counterparts. Furthermore, the mRNA expressions of ABCB1, BCRP, ABCB5 and EGFR were not related to the 50% inhibition concentrations (IC50) for BetA in a panel of 60 cell lines of the National Cancer Institute (NCI), USA. In addition to well-established MDR mechanisms, we attempted to identify other molecular mechanisms that play a role in mediating BetA's cytotoxic activity. For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell lines panel. Various genes significantly correlating to BetA's activity were involved in different biological processes, e.g., cell cycle regulation, microtubule formation, signal transduction, transcriptional regulation, chromatin remodeling, cell adhesion, tumor suppression, ubiquitination and proteasome degradation. Immunoblotting and in silico analyses revealed that the inhibition of AMFR activity might be one of the mechanisms for BetA to overcome MDR phenotypes. In conclusion, BetA may have therapeutic potential for the treatment of refractory tumors.